These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domain. Hobbs CJ; Bit RA; Cansfield AD; Harris B; Hill CH; Hilyard KL; Kilford IR; Kitas E; Kroehn A; Lovell P; Pole D; Rugman P; Sherborne BS; Smith IE; Vesey DR; Walmsley DL; Whittaker D; Williams G; Wilson F; Banner D; Surgenor A; Borkakoti N Bioorg Med Chem Lett; 2002 May; 12(10):1365-9. PubMed ID: 11992778 [TBL] [Abstract][Full Text] [Related]
8. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594 [TBL] [Abstract][Full Text] [Related]
9. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Burchat AF; Calderwood DJ; Hirst GC; Holman NJ; Johnston DN; Munschauer R; Rafferty P; Tometzki GB Bioorg Med Chem Lett; 2000 Oct; 10(19):2171-4. PubMed ID: 11012022 [TBL] [Abstract][Full Text] [Related]
10. Discovery of thienopyridines as Src-family selective Lck inhibitors. Abbott L; Betschmann P; Burchat A; Calderwood DJ; Davis H; Hrnciar P; Hirst GC; Li B; Morytko M; Mullen K; Yang B Bioorg Med Chem Lett; 2007 Mar; 17(5):1167-71. PubMed ID: 17234410 [TBL] [Abstract][Full Text] [Related]
11. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778 [TBL] [Abstract][Full Text] [Related]
12. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Arnold LD; Calderwood DJ; Dixon RW; Johnston DN; Kamens JS; Munschauer R; Rafferty P; Ratnofsky SE Bioorg Med Chem Lett; 2000 Oct; 10(19):2167-70. PubMed ID: 11012021 [TBL] [Abstract][Full Text] [Related]
13. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052 [TBL] [Abstract][Full Text] [Related]
14. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency. Chen P; Iwanowicz EJ; Norris D; Gu HH; Lin J; Moquin RV; Das J; Wityak J; Spergel SH; de Fex H; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC Bioorg Med Chem Lett; 2002 Nov; 12(21):3153-6. PubMed ID: 12372522 [TBL] [Abstract][Full Text] [Related]
16. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors. Li J; Du J; Xi L; Liu H; Yao X; Liu M Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675 [TBL] [Abstract][Full Text] [Related]
17. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148 [TBL] [Abstract][Full Text] [Related]
18. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights. Elkamhawy A; Ali EMH; Lee K J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1574-1602. PubMed ID: 34233563 [TBL] [Abstract][Full Text] [Related]
19. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I. Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846 [TBL] [Abstract][Full Text] [Related]
20. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck). Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]